New androgen receptor genomic targets show an interaction with the ETS1 transcription factor
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
The androgen receptor (AR) initiates important developmental and oncogenic transcriptional pathways. The AR is known to bind as a homodimer to 15-base pair bipartite palindromic androgen-response elements; however, few direct AR gene targets are known. To identify AR promoter targets, we used chromatin immunoprecipitation with on-chip detection of genomic fragments. We identified 1,532 potential AR-binding sites, including previously known AR gene targets. Many of the new AR target genes show altered expression in prostate cancer. Analysis of sequences underlying AR-binding sites showed that more than 50% of AR-binding sites did not contain the established 15 bp AR-binding element. Unbiased sequence analysis showed 6-bp motifs, which were significantly enriched and were bound directly by the AR in vitro. Binding sequences for the avian erythroblastosis virus E26 homologue (ETS) transcription factor family were also highly enriched, and we uncovered an interaction between the AR and ETS1 at a subset of AR promoter targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Such a situation has also been observed for similar studies on the androgen receptor and may suggest compensation or redundancy in transcriptional control (Massie et al., 2007).”
From Dissecting the Unique Role of the Retinoblastoma Tumor Suppressor during Cellular Senescence (2010) · cites this paper as Massie et al., 2007
In the citing paper
“The involvement of the AR in normal prostate development, coupled with the prevalence of ETS-binding sequences at AR-bound regions (177), implies a cooperative interaction that could play a role in ETS-mediated prostate oncogenesis (Figure 7).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [177]
In the citing paper
“AR has evolved in a manner that allows it to tolerate levels of sequence degeneracy for proper development, with this enhanced flexibility conferred through a plastic dimer interface and an extended hinge, both serving as regulatory mechanisms that allow AR to bind primarily half sites and other degenerate sequences in vivo”
From Allosteric interactions prime androgen receptor dimerization and activation (2022) · cites this paper as Massie et al., 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278 · cited 3×
“EMBO open New androgen receptor genomic targets show an interaction with the ETS1 transcription factor”
BackgroundMatInspector and beyond: promoter analysis based on transcription factor binding sites
Cartharius, K., Frech, K., Grote, K., Klocke, B., Haltmeier, M., Klingenhoff, A., Frisch, M., Bayerlein, M., & Werner, T. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti473 · Cited by 1,979
Carroll, J. S., Liu, X. S., Brodsky, A. S., Li, W., Meyer, C. A., Szary, A. J., Eeckhoute, J., Shao, W., Hestermann, E. V., Geistlinger, T. R., et al. (2005) · Cell · doi:10.1016/j.cell.2005.05.008 · Cited by 1,384
Cancer incidence and mortality in Europe, 2004
Boyle, P., & Ferlay, J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi098 · Cited by 1,217
Cancer incidence and mortality in Europe
Levi, F., Maisonneuve, P., Filiberti, R., La Vecchia, C., & Boyle, P. (1989) · Sozial- und Präventivmedizin · doi:10.1007/bf02148558 · Cited by 968
Integrative molecular concept modeling of prostate cancer progression
Tomlins, S. A., Mehra, R., Rhodes, D. R., Cao, X., Wang, L., Dhanasekaran, S. M., Kalyana-Sundaram, S., Wei, J. T., Rubin, M. A., Pienta, K. J., et al. (2007) · Nature Genetics · doi:10.1038/ng1935 · Cited by 922
Varambally, S., Yu, J., Laxman, B., Rhodes, D. R., Mehra, R., Tomlins, S. A., Shah, R. B., Chandran, U., Monzon, F. A., Becich, M. J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.001 · Cited by 800
Holzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63112-4 · Cited by 577 · cited 1×
“Gene Ontology analysis Oncogenomics Haag et al (2005) Velsaco et al (2004) Holzbeierlein et al (2004) Varambally et al (2005) A”
Hata, A., Seoane, J., Lagna, G., Montalvo, E., Hemmati-Brivanlou, A., & Massagué, J. (2000) · Cell · doi:10.1016/s0092-8674(00)81561-5 · Cited by 420
Cited by
Benchmark and integration of resources for the estimation of human transcription factor activities
Garcia-Alonso, L., Holland, C. H., Ibrahim, M. M., Turei, D., & Saez-Rodriguez, J. (2019) · Genome Research · doi:10.1101/gr.240663.118 · Cited by 1,122
Yu, J., Yu, J., Mani, R.-S., Cao, Q., Brenner, C. J., Cao, X., Wang, X., Wu, L., Li, J., Hu, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.018 · Cited by 850
“Interestingly, ETS motifs were found enriched in the androgen receptor (AR) binding sites determined by chromatin immunoprecipitation (ChIP)-on-chip analysis and ETS1, another member of the ETS family transcription factors, was shown to physically interact with AR (Massie et al., 2007).”
BackgroundHeemers, H. V., & Tindall, D. J. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0019 · Cited by 753
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis
Massie, C. E., Lynch, A., Ramos‐Montoya, A., Boren, J., Stark, R., Fazli, L., Warren, A., Scott, H., Madhu, B., Sharma, N., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.158 · Cited by 624
“Over the last 5 years a number of groups have employed ChIP to map genomic binding sites for the AR as a stepping stone to explain the contribution of the AR to prostate cancer (Jariwala et al, 2007; Massie et al, 2007; Takayama et al, 2007; Wang et al, 2007, 2009; Jia et al, 2008).”
BackgroundMethodInfluentialSelf-citationGenomic and biochemical insights into the specificity of ETS transcription factors
Hollenhorst, P. C., McIntosh, L. P., & Graves, B. J. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.79.081507.103945 · Cited by 490
“The involvement of the AR in normal prostate development, coupled with the prevalence of ETS-binding sequences at AR-bound regions (177), implies a cooperative interaction that could play a role in ETSmediated prostate oncogenesis (Figure 7).”
Sharma, N. L., Massie, C. E., Ramos-Montoya, A., Zecchini, V., Scott, H. E., Lamb, A. D., MacArthur, S., Stark, R., Warren, A. Y., Mills, I. G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.010 · Cited by 405
Self-citationDissecting the Unique Role of the Retinoblastoma Tumor Suppressor during Cellular Senescence
Chicas, A., Wang, X., Zhang, C., McCurrach, M., Zhao, Z., Mert, O., Dickins, R. A., Narita, M., Zhang, M., & Lowe, S. W. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.023 · Cited by 388
“Such a situation has also been observed for similar studies on the androgen receptor and may suggest compensation or redundancy in transcriptional control (Massie et al., 2007).”
Genetic and molecular insights into the development and evolution of sexual dimorphism
Williams, T. M., & Carroll, S. B. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2687 · Cited by 338
“Each steroid receptor has DNA-binding domains and regulates gene activity by binding to target CREs in collaboration with other DNA-binding protein”
ETS gene fusions in prostate cancer
Clark, J. P., & Cooper, C. S. (2009) · Nature Reviews Urology · doi:10.1038/nrurol.2009.127 · Cited by 276
“One mechanism of note is a new model of AR migration and DNA binding in which the AR interacts directly with ETS proteins in the presence and absence of androgens”
BackgroundLawrence, M. G., Lai, J., & Clements, J. A. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0034 · Cited by 265
Cooperative interaction between retinoic acid receptor-α and estrogen receptor in breast cancer
Ross-Innes, C. S., Stark, R., Holmes, K. A., Schmidt, D., Spyrou, C., Russell, R., Massie, C. E., Vowler, S. L., Eldridge, M., & Carroll, J. S. (2010) · Genes & Development · doi:10.1101/gad.552910 · Cited by 260
“However, more recently, it has been observed in ChIP-on-chip and ChIP-seq data that, in a chromatin context, various nuclear receptors, including ER and RARa, can bind to a single half-site (Carroll et al. 2005; Lin et al. 2007; Massie et al. 2007; Wang et al. 2007) or widely spaced half-sites (Kato et al.”
BackgroundSelf-citationSun, C., Dobi, A., Mohamed, A., Li, H., Thangapazham, R. L., Furusato, B., Shaheduzzaman, S., Tan, S.-H., Vaidyanathan, G., Whitman, E., et al. (2008) · Oncogene · doi:10.1038/onc.2008.183 · Cited by 253
“As both of these genes are regulated by AR and frequent overlap between AREs and ETS-binding sites have been reported (Massie et al., 2007), we evaluated the ERGdependent recruitment of the AR to the PSA enhancer (AREIII), and SLC45A3 (prostein) ARE elements.”
BackgroundETV1, 4 and 5: An oncogenic subfamily of ETS transcription factors
Oh, S., Shin, S., & Janknecht, R. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.02.002 · Cited by 249
Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
Attard, G., Cooper, C. S., & de Bono, J. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.11.006 · Cited by 242
“Despite this prodifferentiation function, androgenregulated genes are overexpressed in primary prostate cancer and CRPC compared with benign prostate epithelia, and downregulation of these genes is associated with clinical responses to androgen ablation therapy (Massie et al., 2007).”
BackgroundDiverse roles of androgen receptor (AR) domains in AR-mediated signaling
Claessens, F., Denayer, S., Van Tilborgh, N., Kerkhofs, S., Helsen, C., & Haelens, A. (2008) · Nuclear Receptor Signaling · doi:10.1621/nrs.06008 · Cited by 231
“…the nuclear localization signal affects the intracellular location of the AR, as well as its DNA binding, and has also been shown to increase or prevent specific coregulator interactions, receptor folding and receptor aggregation [Faus and Haendler, 2006; Haelens et al., 2007; Thomas et al., 2004].”
The role of the transcription factor Ets1 in carcinoma
Dittmer, J. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.09.010 · Cited by 212
Mechanisms of transcriptional repression by histone lysine methylation
Hublitz, P., Albert, M., Hfmpeters, A., Hublitz, P., Albert, M., & Peters, A. H. F. M. (2009) · The International Journal of Developmental Biology · doi:10.1387/ijdb.082717ph · Cited by 207
Handa, R. J., Pak, T. R., Kudwa, A. E., Lund, T. D., & Hinds, L. (2008) · Hormones and Behavior · doi:10.1016/j.yhbeh.2007.09.012 · Cited by 205
“The classical DNA target for ER is the estrogen response element (ERE) and for AR, is the androgen response element (ARE), however, many hormone responsive genes lack these elements (Massie et al, 2007).”
BackgroundIntegration of Regulatory Networks by NKX3-1 Promotes Androgen-Dependent Prostate Cancer Survival
Tan, P. Y., Chang, C. W., Chng, K. R., Wansa, K. D. S. A., Sung, W.-K., & Cheung, E. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.05958-11 · Cited by 180
“Besides using high-throughput technology to determine the number of ARBS in the prostate cancer genome, several groups have tried to refine the sequence of the ARE motif (9, 48, 67).”
BackgroundMethodMaintaining and reprogramming genomic androgen receptor activity in prostate cancer
Mills, I. G. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3678 · Cited by 172
Self-citationNutrition and human health from a sex–gender perspective
Marino, M., Masella, R., Bulzomi, P., Campesi, I., Malorni, W., & Franconi, F. (2011) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.02.001 · Cited by 175
“…response elements (ARE) in the upstream promoter of target genes and, along with several co-regulator proteins (co-activators and co-repressors), leads to the transcriptional activation of androgen-regulated genes (Berry et al., 2008; Massie et al., 2007; Shang et al., 2002; Wang et al., 2007).”
BackgroundSvensson, C., Ceder, J., Iglesias-Gato, D., Chuan, Y.-C., Pang, S. T., Bjartell, A., Martinez, R. M., Bott, L., Helczynski, L., Ulmert, D., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt921 · Cited by 153
“This analysis corroborate previous findings that induction of AR binding to promoter regions on DHT treatment does not generally correlate with changes in mRNA levels for the neighboring genes, but for a minority of genes [Figure 1B and (13)].”
InfluentialA transcriptional repressor co‐regulatory network governing androgen response in prostate cancers
Chng, K. R., Chang, C. W., Tan, S. K., Yang, C., Hong, S. Z., Sng, N. Y. W., & Cheung, E. C. W. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.112 · Cited by 167
“Intriguingly, in contrast to its counterparts ETS1 and ETV1 (Massie et al , 2007; Shin et al , 2009), ERG was shown to attenuate AR-dependent transcription (Sun et al , 2008; Yu et al , 2010b).”
Ferreira, L. B., Palumbo, A., de Mello, K. D., Sternberg, C., Caetano, M. S., de Oliveira, F. L., Neves, A. F., Nasciutti, L. E., Goulart, L. R., & Gimba, E. R. P. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-507 · Cited by 176
The Rules of DNA Recognition by the Androgen Receptor
Denayer, S., Helsen, C., Thorrez, L., Haelens, A., & Claessens, F. (2010) · Molecular Endocrinology · doi:10.1210/me.2009-0310 · Cited by 148
“Because UN-ARE was originally described in a genomic AR-binding fragment in LNCaP cells (19), we also tested the reporter constructs based on the UNQ promoter in LNCaP and VCaP cells.”
BackgroundInfluentialJia, L., Berman, B. P., Jariwala, U., Yan, X., Cogan, J. P., Walters, A., Chen, T., Buchanan, G., Frenkel, B., & Coetzee, G. A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003645 · Cited by 148
“For this reason, two studies that used genomic windows around the TSSs of annotated genes may have been limited in their capacity to assign ARORs in a genome-wide fashion [4,5] by missing functional ARORs far away on linear DNA.”
BackgroundStructural basis for nuclear hormone receptor DNA binding
Helsen, C., Kerkhofs, S., Clinckemalie, L., Spans, L., Laurent, M. R., Boonen, S., Vanderschueren, D., & Claessens, F. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.07.025 · Cited by 180
Nuclear Receptors: One Big Family
McEwan, I. J. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-575-0_1 · Cited by 173
Centenera, M. M., Harris, J. M., Tilley, W. D., & Butler, L. M. (2008) · Molecular Endocrinology · doi:10.1210/me.2008-0017 · Cited by 145
Urbanucci, A., Sahu, B., Seppälä, J., Larjo, A., Latonen, L., Waltering, K. K., Tammela, T. L. J., Vessella, R. L., Lähdesmäki, H. J., Jänne, O. A., et al. (2011) · Oncogene · doi:10.1038/onc.2011.401 · Cited by 155
“Unlike most of the previous AR ChIP-chip and ChIPseq studies (Massie et al., 2007; Wang et al., 2007, 2009; Jia et al., 2008; Takayama et al., 2010; Yu et al., 2010), we used several ligand concentrations and several LNCaP derivative cell lines.”
MethodResultStepwise androgen receptor dimerization
van Royen, M. E., van Cappellen, W. A., de Vos, C., Houtsmuller, A. B., & Trapman, J. (2012) · Journal of Cell Science · doi:10.1242/jcs.096792 · Cited by 143
Determinants of Receptor- and Tissue-Specific Actions in Androgen Signaling
Pihlajamaa, P., Sahu, B., & Jänne, O. A. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1034 · Cited by 141
Feng, H., Cheng, A. S. L., Tsang, D. P., Li, M. S., Go, M. Y., Cheung, Y. S., Zhao, G.-J., Ng, S. S., Lin, M. C., Yu, J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45967 · Cited by 141
Molecular mechanisms of ETS transcription factor-mediated tumorigenesis
Kar, A., & Gutierrez‐Hartmann, A. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.838202 · Cited by 169
“ETS-1 in turn stimulates DNA binding activity of AML-1 by associating with its NEDB (negative regulatory domain for DNA binding) domain.”
BackgroundInfluentialCooperation between Polycomb and androgen receptor during oncogenic transformation
Zhao, J. C., Yu, J., Runkle, C., Wu, L., Hu, M., Wu, D., Liu, J. S., Wang, Q., Qin, Z. S., & Yu, J. (2011) · Genome Research · doi:10.1101/gr.131508.111 · Cited by 148
“Using chromatin immunoprecipitation (ChIP)–based assays, global AR binding events have been gradually mapped first by region-limited DNA microarrays (Massie et al. 2007) and later by genome-tiling arrays (Wang et al. 2009) and ChIP-seq assays (Jia et al. 2008; Lin et al. 2009; Yu et al. 2010b;…”
Allosteric Modulators of Steroid Hormone Receptors: Structural Dynamics and Gene Regulation
Kumar, R., & McEwan, I. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1033 · Cited by 135
Molecular and cellular mechanisms of castration resistant prostate cancer (Review)
Huang, Y., Jiang, X., Liang, X., & Jiang, G. (2018) · Oncology Letters · doi:10.3892/ol.2018.8123 · Cited by 192
Li, R., Brockschmidt, F. F., Kiefer, A. K., Stefansson, H., Nyholt, D. R., Song, K., Vermeulen, S. H., Kanoni, S., Glass, D., Medland, S. E., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002746 · Cited by 127
“Although a large number of genes were found to be targets of AR, no AR binding sites have been identified in any of the candidate genes at AGA loci [32,33].”
BackgroundWilson, S., Qi, J., & Filipp, F. V. (2016) · Scientific Reports · doi:10.1038/srep32611 · Cited by 126
“AREs can be modulated by cooperation with other transcription factors, which can compensate for missing canonical contacts of imperfect AREs and nevertheless result in successful gene expression events 23,55 .”
Snoek, R., Cheng, H., Margiotti, K., Wafa, L. A., Wong, C. A., Wong, E. C., Fazli, L., Nelson, C. C., Gleave, M. E., & Rennie, P. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1726 · Cited by 131
Androgen receptor coregulators: recruitment via the coactivator binding groove
van de Wijngaart, D. J., Dubbink, H. J., van Royen, M. E., Trapman, J., & Jenster, G. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.08.007 · Cited by 122
Stelloo, S., Nevedomskaya, E., Kim, Y., Hoekman, L., Bleijerveld, O. B., Mirza, T., Wessels, L. F. A., van Weerden, W. M., Altelaar, A. F. M., Bergman, A. M., et al. (2018) · Oncogene · doi:10.1038/onc.2017.330 · Cited by 118
Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines
Rizza, P., Barone, I., Zito, D., Giordano, F., Lanzino, M., Amicis, F. D., Mauro, L., Sisci, D., Catalano, S., Wright, K. D., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3619 · Cited by 114
“Indeed, ChIP-on-chip data revealed that the AR binds to genomic regions that contain DNA elements which might consist of simple 5 ′ -TGTTCT-3 ′ -like monomer binding sites [54,59,60].”
Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer
on behalf of the Transatlantic Prostate Group, Attard, G., Clark, J., Ambroisine, L., Mills, I. G., Fisher, G., Flohr, P., Reid, A. H. M., Edwards, S. E., Kovács, G., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604472 · Cited by 117
“Both Massie et al (2007) and Wang et al (2007) have proposed mechanisms for AR recruitment to subsets of target sequences through associations between the AR and other transcription factors for example, GATA-2, OCT11, FOXA1 and ETS1.”
BackgroundSelf-citationTakayama, K., Tsutsumi, S., Katayama, S., Okayama, T., Horie‐Inoue, K., Ikeda, K., Urano, T., Kawazu, C., Hasegawa, A., Ikeo, K., et al. (2010) · Oncogene · doi:10.1038/onc.2010.436 · Cited by 114
“Our group and others have successfully determined bonafide AR binding sites (ARBSs) in the human genome by chromatin immunoprecipitation (ChIP) analysis combined with genome tiling arrays (ChIP-chip) (Massie et al., 2007; Takayama et al., 2007, 2009; Wang et al., 2007, 2009).”
Sun, D., Layer, R. M., Mueller, A. C., Cichewicz, M. A., Negishi, M., Paschal, B. M., & Dutta, A. (2013) · Oncogene · doi:10.1038/onc.2013.77 · Cited by 103
“Such half-ARE sites can bind to AR both in vitro and in vivo (6, 54).”
BackgroundUnderstanding the Role of ETS-Mediated Gene Regulation in Complex Biological Processes
Findlay, V. J., LaRue, A. C., Turner, D. P., Watson, P. M., & Watson, D. K. (2013) · Advances in cancer research · doi:10.1016/b978-0-12-407190-2.00001-0 · Cited by 125
Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability
Munkley, J., Vodák, D., Livermore, K., James, K., Wilson, B. T., Knight, B., McCullagh, P., Mcgrath, J., Crundwell, M., Harries, L., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.018 · Cited by 99
“However, these studies have generally focused either on the use of a single model of prostate cancer (LNCaP or its in vitro derived subclones) (Massie et al., 2007; Wang et al., 2007; Rajan et al., 2011), only on AR regulated genes with nearby AR genomic binding sites (Massie et al.”
BackgroundSelf-citationNaji, M., Aleyasin, A., Nekoonam, S., Arefian, E., Mahdian, R., & Amidi, F. (2017) · Scientific Reports · doi:10.1038/s41598-017-13250-1 · Cited by 109
Androgen receptor genomic regulation.
Jin, H., Kim, J., & Yu, J. (2013) · PubMed Central · doi:10.3978/j.issn.2223-4683.2013.09.01 · Cited by 139
“Although AR is thought to have high affinity binding with canonical full AREs, a majority of the ARBS were found to bind primarily half AREs (59-61).”
BackgroundMethodResultInfluentialThe Androgen Receptor and VEGF: Mechanisms of Androgen-Regulated Angiogenesis in Prostate Cancer
Eisermann, K., & Fraizer, G. C. (2017) · Cancers · doi:10.3390/cancers9040032 · Cited by 103
Handa, R. J., Weiser, M. J., & Zuloaga, D. G. (2009) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2009.01840.x · Cited by 96
Wyce, A., Bai, Y., Nagpal, S., & Thompson, C. C. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0138 · Cited by 105
“(9), suggesting that the tissue-specific response of certain genes to androgen signaling may be due, in part, to the”
BackgroundAndrogen receptor signalling in prostate: Effects of stromal factors on normal and cancer stem cells
Berry, P. A., Maitland, N. J., & Collins, A. T. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.02.024 · Cited by 114
“These non-canonical sites, some of which were frequently repeated, are thought to be more important for enhancer promoter function (Wang et al., 2007; Massie et al., 2007).”
BackgroundIntrinsic disorder in the androgen receptor: identification, characterisation and drugability
McEwan, I. J. (2011) · Molecular BioSystems · doi:10.1039/c1mb05249g · Cited by 86
Fan, J., Traore, K., Li, W., Amri, H., Huang, H., Wu, C. H., Chen, H., Zirkin, B. R., & Papadopoulos, V. (2010) · Endocrinology · doi:10.1210/en.2010-0010 · Cited by 98
Need, E. F., Selth, L. A., Harris, T. J., Birrell, S. N., Tilley, W. D., & Buchanan, G. (2012) · Molecular Endocrinology · doi:10.1210/me.2011-1314 · Cited by 97
Genomic Analyses of Hormone Signaling and Gene Regulation
Cheung, E. C. W., & Kraus, W. L. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135840 · Cited by 95
Quartier, A., Chatrousse, L., Redin, C., Keime, C., Haumesser, N., Maglott-Roth, A., Brino, L., Le Gras, S., Benchoua, A., Mandel, J.-L., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.01.002 · Cited by 86
Schmidt, K., Carroll, J. S., Yee, E., Thomas, D. D., Wert-Lamas, L., Neier, S. C., Sheynkman, G., Ritz, J., & Novina, C. D. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.101 · Cited by 103
“Our AR ChIP-seq analysis faithfully identified several known AR target genes, including C15orf40, POLR2A, and WDR70 (average peak intensities, 60–110), as well as known ligand-independent AR targets, including NR6A1, MIPEP, and WWOX (average peak intensities, 40– 175; Figure 3A) (Lin et al., 2009; Massie et al., 2007;…”
Shin, S., Kim, T.-D., Jin, F., van Deursen, J. M., Dehm, S. M., Tindall, D. J., Grande, J. P., Munz, J.-M., Vasmatzis, G., & Janknecht, R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0941 · Cited by 85
Lin, B., Wang, J., Hong, X., Yan, X., Hwang, D., Cho, J.-H., Yi, D., Utleg, A. G., Fang, X., Schones, D. E., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006589 · Cited by 81
“This maybe not surprising as the consensus sequences for the AR in the Transfac database are derived either from in vitro binding data or from a limited numbers of human promoters: the M00481 (consensus: GGTACANNRTGTTCT) was built from 29 binding sites selected from random oligonucleotides [25]; M00447 (consensus sequ…”
InfluentialPignon, J., Koopmansch, B., Nolens, G., Delacroix, L., Waltregny, D., & Winkler, R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3760 · Cited by 89
Transcriptional network of androgen receptor in prostate cancer progression
Takayama, K., & Inoue, S. (2013) · International Journal of Urology · doi:10.1111/iju.12146 · Cited by 90
Rajan, P., Gaughan, L., Dalgliesh, C., El‐Sherif, A., Robson, C. N., Leung, H. Y., & Elliott, D. J. (2008) · The Journal of Pathology · doi:10.1002/path.2324 · Cited by 88
“In the light of evidence implicating CD44 as an AR-target gene [19] and its splice variants in PCa [8], we considered the possibility that AR and Sam68 may act synergistically on CD44 splicing.”
BackgroundResultPTP1B Is an Androgen Receptor–Regulated Phosphatase That Promotes the Progression of Prostate Cancer
Lessard, L., Labbé, D. P., Deblois, G., Bégin, L. R., Hardy, S., Mes-Masson, A.-M., Saad, F., Trotman, L. C., Giguère, V., & Tremblay, M. L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2602 · Cited by 79
“Because the location of AREs is not restricted to gene promoter regions and often contains degeneratedmotifs (21, 22), we designed a highresolution tiled microarray spanning the entire human 20q chromosome enclosing PTPN1 to carry out location analysis of AR by ChIP hybridized to the array (ChIP-on-chip) in R1881treat…”
ChIPping away at gene regulation
Massie, C. E., & Mills, I. G. (2008) · EMBO reports · doi:10.1038/embor.2008.44 · Cited by 77
“…tF consensus binding motifs for their targets are relatively enriched in chip data; for example, notcH (P = 1 × 10–13), androgen recep tor (ar; P < 2 × 10–6) and glucocorticoid receptor (gr; P < 0.05; supplementary table 1 online; Massie et al, 2007; palomero et al, 2006; phuc le et al, 2005).”
BackgroundMethodInfluentialSelf-citationTakayama, K., Suzuki, T., Tsutsumi, S., Fujimura, T., Urano, T., Takahashi, S., Homma, Y., Aburatani, H., & Inoue, S. (2014) · Oncotarget · doi:10.18632/oncotarget.2949 · Cited by 78
“To determine the genomic distribution of AR binding sites, it is important to consider binding sites for AR collaborating transcription factors such as FOXA1 [3, 4], NKX3-1 [5], GATA2, OCT1 [3] and members of the ETS family of transcription factors [6, 7].”
β-Adrenergic Receptor Signaling in Prostate Cancer
Braadland, P. R., Ramberg, H., Grytli, H. H., & Taskén, K. A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2014.00375 · Cited by 87
Swift, S. L., Burns, J. E., & Maitland, N. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1252 · Cited by 71
Mini-review: Foldosome regulation of androgen receptor action in prostate cancer
Cano, L. Q., Lavery, D. N., & Bevan, C. L. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.01.023 · Cited by 82
Androgen receptor-mediated gene repression
Grosse, A., Bartsch, S., & Baniahmad, A. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.06.032 · Cited by 69
“Many putative AREs and negatively regulated genes were identified in human PCa cell lines, such as PC3–AR (Lin et al., 2009), and LNCaP cells (Nelson et al., 2002; Messie et al., 2007).”
Androgen Modulation of Coregulator Expression in Prostate Cancer Cells
Heemers, H. V., Regan, K. M., Schmidt, L. J., Anderson, S. K., Ballman, K. V., & Tindall, D. J. (2009) · Molecular Endocrinology · doi:10.1210/me.2008-0363 · Cited by 77
Comparing the rules of engagement of androgen and glucocorticoid receptors
Claessens, F., Joniau, S., & Helsen, C. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2467-3 · Cited by 74
The role of androgen receptor in breast cancer
Iacopetta, D., Rechoum, Y., & Fuqua, S. A. W. (2012) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2012.11.003 · Cited by 77
“Additionally, different selective AREs have been reported to be specifically regulated by AR, but not any other steroid receptor, that we are not detailing here for the sake of brevity but could be reviewed in [20-23], [24], [25] [26] [27-29].”
BackgroundKhanna, A., Okkeri, J., Bilgen, T., Tiirikka, T., Vihinen, M., Visakorpi, T., & Westermarck, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017979 · Cited by 67
“Interestingly, in the same experiment CIP2A enrichment was even stronger than UNQ9419, an established ETS1 target that was used as a positive control [30].”
BackgroundMarshall, E., Lowrey, J., MacPherson, S., Maybin, J. A., Collins, F., Critchley, H. O. D., & Saunders, P. T. K. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0272 · Cited by 66
“Our strategy included data sets based on ChIP-onchip (11, 12) conducted using in prostate cancer-derived epithelial cells treated for short duration with androgen.”
BackgroundMethodInfluentialNuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer
Zecchini, V. R., Madhu, B., Russell, R. R., Pértega‐Gomes, N., Warren, A. Y., Gaude, E., Borlido, J., Stark, R., Zecchini, H. I., Rao, R. B., et al. (2014) · The EMBO Journal · doi:10.15252/embj.201386874 · Cited by 66
“Metabolite peak assignment was done from the literature values (Massie et al, 2007) and also using 2D spectra (COSY and TOCSY).”
MethodSelf-citationPatki, M., Chari, V., Sivakumaran, S., Gonit, M., Trumbly, R. J., & Ratnam, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.438473 · Cited by 76
“ETS1 may also directly associate with AR, but its physiological significance is yet to be understood (46).”
BackgroundRhoA as a Mediator of Clinically Relevant Androgen Action in Prostate Cancer Cells
Schmidt, L. J., Duncan, K., Yadav, N., Regan, K. M., Verone, A. R., Lohse, C. M., POP, E. A., Attwood, K. M., Wilding, G. E., Mohler, J. L., et al. (2012) · Molecular Endocrinology · doi:10.1210/me.2011-1130 · Cited by 75
Androgen Receptor-Target Genes in African American Prostate Cancer Disparities
Wang, B., Yang, Q., Ceniccola, K., Bianco, F. J., Andrawis, R., Jarrett, T. W., Frazier, H. A., Patierno, S. R., & Lee, N. H. (2013) · Prostate Cancer · doi:10.1155/2013/763569 · Cited by 62
“We have also compared our AR-target gene list with ChIP-chip and ChIP-seq data derived from the CA PCa cell lines LNCaP, VCaP, and PC3 [75–77]. ere were 147 AR-target genes from our dataset in common with the ChIP-chip or ChIP-seq datasets. is partial overlap is not unexpected given our criteria for identifyingAR-targ…”
BackgroundInfluentialHu, S., Yao, G., Guan, X., Ni, Z., Ma, W., Wilson, E. M., French, F. S., Liu, Q., & Zhang, Y. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0226 · Cited by 65
“This result is in accordance with previous findings on AR (12, 14) and other transcription factors (38).”
BackgroundResultDNA‐Binding Small Molecules as Inhibitors of Transcription Factors
Leung, C., Chan, D. S., Ma, V. P., & Ma, D. (2013) · Medicinal Research Reviews · doi:10.1002/med.21266 · Cited by 58
Glycosylation is a global target for androgen control in prostate cancer cells
Munkley, J. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0569 · Cited by 64
Sharma, N. L., Massie, C. E., Butter, F., Mann, M., Bon, H., Ramos‐Montoya, A., Menon, S., Stark, R., Lamb, A. D. G., Scott, H. E., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku281 · Cited by 60
“A subset of the core GABP differentially expressed genes were known AR targets from previous ChIP studies in PC (22) (33% of, n = 1046 Figure 3A, P < 0.”
BackgroundMethodResultInfluentialSelf-citationThe importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance
Zarif, J. C., & Miranti, C. K. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.01.013 · Cited by 62
“Once AR is in the nucleus, dimeric AR binds to androgen response elements (AREs) in the promoters or enhancers of target genes.”
InfluentialShen, Q., Bai, Y., Chang, K. C. N., Wang, Y., Burris, T. P., Freedman, L. P., Thompson, C. C., & Nagpal, S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.165704 · Cited by 54
Androgen receptor-driven chromatin looping in prostate cancer
Wu, D., Zhang, C., Shen, Y., Nephew, K. P., & Wang, Q. (2011) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2011.07.006 · Cited by 62
Allosteric interactions prime androgen receptor dimerization and activation
Wasmuth, E. V., Broeck, A. V., LaClair, J. R., Hoover, E. A., Lawrence, K. E., Paknejad, N., Pappas, K., Matthies, D., Wang, B., Feng, W., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.03.035 · Cited by 50
“However, AR’s highly degenerate cistrome is inconsistent with a model whereby dimerization relies on canonical ARE repeats (Massie et al., 2007; Wang et al., 2007; Wilson et al., 2016).”
BackgroundInfluentialWasmuth, E. V., Hoover, E. A., Antar, A., Klinge, S., Chen, Y., & Sawyers, C. L. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922159117 · Cited by 50
“S1G), which have been reported to comprise the vast majority of AR binding sites in PCa cells (23, 24, 33).”
BackgroundMesenchymal mechanisms in prostate organogenesis
Thomson, A. A. (2008) · Differentiation · doi:10.1111/j.1432-0436.2008.00296.x · Cited by 50
Androgen Receptor-Mediated Transcription in Prostate Cancer
Özturan, D., Morova, T., & Lack, N. A. (2022) · Cells · doi:10.3390/cells11050898 · Cited by 58
The transcriptional programme of the androgen receptor ( AR ) in prostate cancer
Lamb, A. D. G., Massie, C. E., & Neal, D. E. (2014) · British Journal of Urology · doi:10.1111/bju.12415 · Cited by 58
Self-citationIbuki, N., Ghaffari, M., Reuveni, H., Pandey, M., Fazli, L., Azuma, H., Gleave, M. E., Levitzki, A., & Cox, M. E. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0842 · Cited by 51
“Of the IRS family, only IRS4 was identified as an AR target gene by ChIP analysis (33); however, in the Androgen Responsive Gene Database (http://argdb.”
BackgroundJin, F., & Fondell, J. D. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp510 · Cited by 49
“It has been reported that binding sites for the GATA and ETS families of transcription factors are enriched proximal to cognate AR-binding sites in the genome and may play cooperative roles in mediating an androgen response (3,5,35).”
BackgroundMert, U., & Şanlioğlu, A. D. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2321-z · Cited by 49
“Consistently, the TNFRSF10B promoter appears in the list of AR binding sites, determined by ChIP analysis (Supplementary data of [56]).”
BackgroundIdentification of a Clinically Relevant Androgen-Dependent Gene Signature in Prostate Cancer
Heemers, H. V., Schmidt, L. J., Sun, Z., Regan, K. M., Anderson, S. K., Duncan, K., Wang, D., Liu, S., Ballman, K. V., & Tindall, D. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2512 · Cited by 45
Obinata, D., Takayama, K., Takahashi, S., & Inoue, S. (2017) · Cancers · doi:10.3390/cancers9030022 · Cited by 53
“[73] reported the enrichment of ETS consensus binding motifs and non-canonical AREs in about 70% of AR binding promoter regions.”
BackgroundBuendía-González, F. O., & Legorreta‐Herrera, M. (2022) · Biomolecules · doi:10.3390/biom12121768 · Cited by 50
Cyclin D1 Is a Selective Modifier of Androgen-dependent Signaling and Androgen Receptor Function
Comstock, C. E. S., Augello, M. A., Schiewer, M. J., Karch, J. M., Burd, C. J., Ertel, A., Knudsen, E. S., Jessen, W. J., Aronow, B. J., & Knudsen, K. E. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.170720 · Cited by 47
Metadata
- Authors
- Massie, C. E., Adryan, B., Barbosa‐Morais, N. L., Lynch, A. G., Tran, M. G., Neal, D. E., & Mills, I. G.
- Affiliations
- University of Cambridge (GB)
- MRC Laboratory of Molecular Biology (GB)
- Corresponding author
- Massie, Charles E
- Mills, Ian G
- ORCID
- Venue
- The EMBO Reports
- Published
- 2007-08-17
- Volume
- 8
- Issue
- 9
- Pages
- 871-878
- ISSN
- 1469-221X (ISSN-L)
- 1469-3178
- PMC
- PMC1950328
- OpenAlex
- W2030465046
- Cited by
- 259
- References
- 25
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 6 · 2023: 8 · 2022: 10 · 2021: 6 · 2020: 5 · 2019: 6 · 2018: 9 · 2017: 15 · 2016: 13 · 2015: 12 · 2014: 14 · 2013: 27 · 2012: 24
- FWCI
- 19.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- EMBO Reports (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Funders
- National Institute for Health and Care Research (CL-2006-14-006)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- androgen receptor, ETS1, transcription factor binding sites, androgen response element, prostate cancer, transcriptional regulation, protein-protein interaction
- MeSH terms
- Base Sequence, Binding Sites, Humans, Molecular Sequence Data, Promoter Regions, Genetic, Protein Binding, Receptors, Androgen, Genome, Human, Sequence Analysis, DNA, Cell Line, Tumor, Chromatin Immunoprecipitation, Proto-Oncogene Protein c-ets-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.